Fusion Antibodies (LON:FAB) Shares Up 3.9% – Should You Buy?

Fusion Antibodies plc (LON:FABGet Free Report)’s stock price traded up 3.9% during trading on Tuesday . The company traded as high as GBX 6.50 ($0.08) and last traded at GBX 6.39 ($0.08). 2,294,034 shares were traded during trading, an increase of 73% from the average session volume of 1,327,368 shares. The stock had previously closed at GBX 6.15 ($0.08).

Fusion Antibodies Stock Up 3.9 %

The firm has a market cap of £6.01 million, a PE ratio of -1.44 and a beta of 0.49. The company has a debt-to-equity ratio of 2.40, a quick ratio of 2.36 and a current ratio of 3.87. The company’s 50-day simple moving average is GBX 7.70 and its two-hundred day simple moving average is GBX 6.26.

About Fusion Antibodies

(Get Free Report)

Fusion is a Belfast based contract research organisation (“CRO”) providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.

The Company’s ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation.

Featured Stories

Receive News & Ratings for Fusion Antibodies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fusion Antibodies and related companies with MarketBeat.com's FREE daily email newsletter.